sorafenib has been researched along with canagliflozin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (canagliflozin) | Trials (canagliflozin) | Recent Studies (post-2010) (canagliflozin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 998 | 194 | 975 |
| Protein | Taxonomy | sorafenib (IC50) | canagliflozin (IC50) |
|---|---|---|---|
| Sodium/glucose cotransporter 1 | Homo sapiens (human) | 0.9497 | |
| Sodium/glucose cotransporter 2 | Homo sapiens (human) | 0.0039 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, Y; Dong, Z; Guo, C; Li, Y; Ma, Y | 1 |
1 other study(ies) available for sorafenib and canagliflozin
| Article | Year |
|---|---|
Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats.
Topics: Animals; Canagliflozin; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Interactions; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Rats; Sodium-Glucose Transporter 2 Inhibitors; Sorafenib | 2022 |